Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock

Prime Medicine intends to give underwriters a 30-day option to purchase up to an additional $18.75 million of common stock.

Rhea-AI Summary

Prime Medicine (Nasdaq: PRME) has commenced a proposed underwritten public offering of $125.0 million of its common stock. All shares in the proposed offering are to be sold by the company. Prime Medicine also intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million of common stock.

The proposed offering is subject to market and other conditions, and its completion, timing, actual size and terms remain uncertain. Jefferies, TD Cowen and Goldman Sachs are acting as joint book-running managers.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.$125.0 million proposed offering would raise equity funding for Prime Medicine. 16% of market cap

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.New common stock in the proposed $125.0 million offering would dilute existing holders. 16% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.30-day underwriter option for up to an additional $18.75 million of shares would add potential dilution.

News Explained

At Q2 2026 cash-use rates, the gross raise equals 277.1 days versus 210.8 days for June 30, 2026 liquidity; final fees determine net proceeds.

Prime Medicine has commenced a proposed $125.0 million underwritten common-stock offering, with the company selling the shares; if completed, issuing them would increase the share count and reduce existing holders’ percentage ownership.

In an underwritten offering, a bank buys securities from the issuer for resale, and underwriting fees reduce net proceeds below the gross amount; the release does not state a net cash amount.

On the same second-quarter 2026 operating-cash-outflow basis, the proposed gross amount equals 277.1 days, compared with 210.8 days represented by cash and short-term investments at June 30, 2026.

The company says a preliminary prospectus supplement describing the offering terms will be filed, and that final terms will be disclosed in the final prospectus supplement.

Sources and calculations

• Prime Medicine proposed public offering release (2026-11-10)
• Underwritten offering definition (undated)
• Dilution definition (undated)
• Prime Medicine second-quarter 2026 fundamentals (2026-06-30)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $125,000,000 / ($41,046,000 / 91) = 277.1 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($47,451,000 + $47,620,000) / ($41,046,000 / 91) = 210.8 days

Argus 15 min delay 50 alerts

-4.61% vs previous close $3.72 last price 1.0x rel. volume Open Argus

Details

Market move: PRME -4.61% vs previous close. $125M public offering

$3.72 – $4.65 Day Range

$674.74M Mkt Cap at Last Price

On Nov 10, the day this news came out, the latest delayed price for PRME is 4.61% below the previous close. Our momentum scanner has recorded 50 alerts for this stock so far that day. The latest delayed price is $3.72.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Proposed offering: $125.0 million Underwriters' option: Up to $18.75 million; 30 days

Proposed offering

$125.0 million

Underwritten public offering of common stock

Underwriters' option

Up to $18.75 million; 30 days

Additional shares of common stock

Previous Offering Reports

2 past events · Latest: Jul 30

Same Type 2 events

1. Jul 30

   Offering pricing

   24h Move

   -4.6%

   Priced 38 million shares at $3.30 each; expected gross proceeds were $125.4 million.

2. Aug 01

   Offering closing

   24h Move

   +11.4%

   Completed a 43.7 million-share offering at $3.30 each, raising $144.2 million gross.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, shelf registration statement, prospectus supplement, book-running managers

4 terms

underwritten public offering financial

"commenced an underwritten public offering of $125.0 million"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3ASR"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement relating to and describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

book-running managers financial

"are acting as joint book-running managers for the proposed offering"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Jefferies, TD Cowen and Goldman Sachs & Co. LLC are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. and LifeSci Capital are acting as passive bookrunning managers for the proposed offering.

The shares of common stock are being offered by Prime Medicine pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2025, as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-291348) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-291348), each filed with the SEC on March 3, 2026, and declared effective by the SEC on March 4, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

When available, copies of the preliminary prospectus supplement relating to the offering may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.

The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around its core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high-value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path.

© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine's beliefs and expectations regarding: the timing, terms and size of the proposed public offering, and the possibility that the proposed offering will be completed on the anticipated terms or at all. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed offering. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Prime Medicine's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine's views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts

Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com

Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much is Prime Medicine seeking to raise in its proposed stock offering?

Prime Medicine has commenced a proposed underwritten offering of $125.0 million of common stock. All shares are to be sold by the company, which also intends to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares.